BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Phase 3

Completed

Conditions: Atrial Fibrillation
Atrial Flutter

Interventions: Drug: warfarin
Drug: apixaban

First Posted Date: 2006-12-19

Last Posted Date: 2018-07-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20976

Registration Number: NCT00412984

Locations: 🇺🇸
David Charles Mishkel, Md, Pa, Boca Raton, Florida, United States
🇺🇸
Heart Care Center, P.C., East Syracuse, New York, United States
🇺🇸
Elkhart Clinic, Llc, Elkhart, Indiana, United States

and more 263 locations

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

Phase 3

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Entecavir + Tenofovir
Drug: Entecavir

First Posted Date: 2006-12-12

Last Posted Date: 2013-03-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 669

Registration Number: NCT00410072

Locations: 🇺🇸
University Of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸
Sergio E. Rojter, Los Angeles, California, United States
🇺🇸
Tuan Nguyen, Md, San Diego, California, United States

and more 14 locations

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

Phase 3

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Adefovir
Drug: Entecavir
Drug: Lamivudine
Drug: Tenofovir

First Posted Date: 2006-12-12

Last Posted Date: 2013-11-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 629

Registration Number: NCT00410202

Locations: 🇺🇸
University Of Connecticut Health Center, Farmington, Connecticut, United States
🇹🇷
Local Institution, Trabzon, Turkey

A Study of Abatacept in Patients With Active Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: abatacept
Drug: abatacept (ABA)
Drug: placebo

First Posted Date: 2006-12-12

Last Posted Date: 2015-03-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 591

Registration Number: NCT00410410

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 48 locations

A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Placebo
Drug: Methotrexate

First Posted Date: 2006-12-11

Last Posted Date: 2013-08-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 113

Registration Number: NCT00409838

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

A Study of Abatacept in Patients With Active Crohn's Disease

Phase 3

Terminated

Conditions: Crohn's Disease

Interventions: Drug: abatacept
Drug: placebo

First Posted Date: 2006-12-04

Last Posted Date: 2010-09-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 451

Registration Number: NCT00406653

Locations: 🇺🇸
Allegheny Center For Digestive Health, Pittsburgh, Pennsylvania, United States
🇺🇸
Consultants For Clinical Research, Cincinnati, Ohio, United States
🇺🇸
Nashville Medical Research, Nashville, Tennessee, United States

and more 35 locations

A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

Phase 2

Completed

Conditions: Renal Transplant

Interventions: Drug: Cyclosporine A
Drug: Belatacept
Drug: Tacrolimus

First Posted Date: 2006-11-22

Last Posted Date: 2017-01-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 173

Registration Number: NCT00402168

Locations: 🇪🇸
Local Institution, Valencia, Spain
🇩🇪
Charite Berlin Mitte, Berlin, Germany
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States

and more 8 locations

Drug Interaction - Oral Contraceptive

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Ortho Cyclen
Drug: Ortho Tri-Cyclen LO
Drug: Ortho Cyclen + Efavirenz

First Posted Date: 2006-11-15

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28

Registration Number: NCT00399685

Locations: 🇺🇸
Covance Clinical Research Unit San Diego, San Diego, California, United States
🇺🇸
Northwest Kinetics, Tacoma, Washington, United States

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-582949
Drug: Placebo

First Posted Date: 2006-11-15

Last Posted Date: 2015-12-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 99

Registration Number: NCT00399906

Locations: 🇲🇽
Local Institution, Monterrey, Nuevo Leon, Mexico

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: BMS-562086

First Posted Date: 2006-11-14

Last Posted Date: 2008-09-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT00399438

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy